Skip to main content
. 2018 Aug 23;23(12):1533–1545. doi: 10.1634/theoncologist.2018-0095

Table 3. Chemotherapy agents and trials.

image

a

Included in the NCCN Guidelines Version 1.2018 Uterine Sarcoma as other options (combination and single agent) [102].

b

Included in the NCCN Guidelines Version 1.2018 Uterine Sarcoma as preferred therapies.

Abbreviations: —, no data; LMS, leiomyosarcoma; N/A, not applicable; NCCN, National Comprehensive Cancer Network; OS, overall survival; PFS, progression‐free survival; STS, soft‐tissue sarcoma; uLMS, uterine leiomyosarcoma.